Novel Potential Agents for Human Cytomegalovirus Infection: Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides
摘要:
The first acyclonucleosides based on the benzothiadiazine dioxide system were synthesized following the silylation procedure. Several acyclic moieties, including acetoxyethoxymethyl, benzyloxymethyl, and propargyloxymethyl groups, were introduced. Two synthetic strategies were designed to selectively obtain the N-1 or N-3 derivatives. Lipase-mediated deacylation was used for the deprotection of the acyclonucleosides. Some of the benzothiadiazine dioxide acyclonucleosides, in particular 16, proved active against human cytomegalovirus (CMV) at concentrations slightly higher than that found for ganciclovir [50% inhibitory concentration (IC50) = 3.5-3.7 mu g/mL, cytotoxicity (CC50) greater than or equal to 40 mu g/mL, MCC 20 mu g/mL]. Additionally, compound 16 inhibited the replication of human immunodeficiency virus type 1 (HTV-1) and HTV-2 in CEM cells at concentrations that were 5-fold lower than its cytotoxic concentration.
Novel Potential Agents for Human Cytomegalovirus Infection: Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides
摘要:
The first acyclonucleosides based on the benzothiadiazine dioxide system were synthesized following the silylation procedure. Several acyclic moieties, including acetoxyethoxymethyl, benzyloxymethyl, and propargyloxymethyl groups, were introduced. Two synthetic strategies were designed to selectively obtain the N-1 or N-3 derivatives. Lipase-mediated deacylation was used for the deprotection of the acyclonucleosides. Some of the benzothiadiazine dioxide acyclonucleosides, in particular 16, proved active against human cytomegalovirus (CMV) at concentrations slightly higher than that found for ganciclovir [50% inhibitory concentration (IC50) = 3.5-3.7 mu g/mL, cytotoxicity (CC50) greater than or equal to 40 mu g/mL, MCC 20 mu g/mL]. Additionally, compound 16 inhibited the replication of human immunodeficiency virus type 1 (HTV-1) and HTV-2 in CEM cells at concentrations that were 5-fold lower than its cytotoxic concentration.
Benzothiadiazine dioxide acyclonucleosides as lead compounds for the development of new agents against human cytomegalovirus and varicella-zoster virus infections
作者:Ana Martinez、Ana I. Esteban、Erik De Clercq
DOI:10.1016/s0960-894x(97)00149-2
日期:1997.4
The first acyclonucleosides derived from 2,1,3-benzothiadiazine dioxides were synthesized. From their antiviral activity evaluation results these compounds might be considered as new leads in the search for inhibitors of human cytomegalovirus (CMV) and varicella-zoster virus (VZV) infections. (C) 1997 Elsevier Science Ltd.
Novel Potential Agents for Human Cytomegalovirus Infection: Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides
作者:Ana Martinez、Ana I. Esteban、Ana Castro、Carmen Gil、Santiago Conde、Graciela Andrei、Robert Snoeck、Jan Balzarini、Erik De Clercq
DOI:10.1021/jm980327z
日期:1999.4.1
The first acyclonucleosides based on the benzothiadiazine dioxide system were synthesized following the silylation procedure. Several acyclic moieties, including acetoxyethoxymethyl, benzyloxymethyl, and propargyloxymethyl groups, were introduced. Two synthetic strategies were designed to selectively obtain the N-1 or N-3 derivatives. Lipase-mediated deacylation was used for the deprotection of the acyclonucleosides. Some of the benzothiadiazine dioxide acyclonucleosides, in particular 16, proved active against human cytomegalovirus (CMV) at concentrations slightly higher than that found for ganciclovir [50% inhibitory concentration (IC50) = 3.5-3.7 mu g/mL, cytotoxicity (CC50) greater than or equal to 40 mu g/mL, MCC 20 mu g/mL]. Additionally, compound 16 inhibited the replication of human immunodeficiency virus type 1 (HTV-1) and HTV-2 in CEM cells at concentrations that were 5-fold lower than its cytotoxic concentration.